- Home
- UGI vs NUVL Comparison
UGI vs NUVL Comparison
Compare UGI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGI
- NUVL
- Stock Information
- Founded
- UGI 1940
- NUVL 2017
- Country
- UGI United States
- NUVL United States
- Employees
- UGI N/A
- NUVL N/A
- Industry
- UGI Natural Gas Distribution
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- UGI Utilities
- NUVL Health Care
- Exchange
- UGI Nasdaq
- NUVL Nasdaq
- Market Cap
- UGI 7.0B
- NUVL 6.5B
- IPO Year
- UGI N/A
- NUVL 2021
- Fundamental
- Price
- UGI $33.75
- NUVL $93.54
- Analyst Decision
- UGI Strong Buy
- NUVL Strong Buy
- Analyst Count
- UGI 2
- NUVL 11
- Target Price
- UGI $33.50
- NUVL $120.00
- AVG Volume (30 Days)
- UGI 1.8M
- NUVL 485.9K
- Earning Date
- UGI 11-20-2025
- NUVL 11-11-2025
- Dividend Yield
- UGI 4.45%
- NUVL N/A
- EPS Growth
- UGI N/A
- NUVL N/A
- EPS
- UGI 1.92
- NUVL N/A
- Revenue
- UGI $7,332,000,000.00
- NUVL N/A
- Revenue This Year
- UGI $10.33
- NUVL N/A
- Revenue Next Year
- UGI $16.58
- NUVL N/A
- P/E Ratio
- UGI $17.60
- NUVL N/A
- Revenue Growth
- UGI N/A
- NUVL N/A
- 52 Week Low
- UGI $23.14
- NUVL $55.54
- 52 Week High
- UGI $37.43
- NUVL $99.94
- Technical
- Relative Strength Index (RSI)
- UGI 58.44
- NUVL 60.16
- Support Level
- UGI $32.87
- NUVL $90.00
- Resistance Level
- UGI $34.09
- NUVL $99.94
- Average True Range (ATR)
- UGI 0.57
- NUVL 4.20
- MACD
- UGI 0.25
- NUVL 0.30
- Stochastic Oscillator
- UGI 86.23
- NUVL 64.33
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.